Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT)

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). / Schou Karlsen, Nikoline Marie; Karlsen, Mona Aarenstrup; Høgdall, Estrid; Nedergaard, Lotte; Christensen, Ib Jarle; Høgdall, Claus.

I: Gynecologic Oncology, Bind 142, Nr. 1, 07.2016, s. 50-3.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Schou Karlsen, NM, Karlsen, MA, Høgdall, E, Nedergaard, L, Christensen, IJ & Høgdall, C 2016, 'Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT)', Gynecologic Oncology, bind 142, nr. 1, s. 50-3. https://doi.org/10.1016/j.ygyno.2016.05.005

APA

Schou Karlsen, N. M., Karlsen, M. A., Høgdall, E., Nedergaard, L., Christensen, I. J., & Høgdall, C. (2016). Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecologic Oncology, 142(1), 50-3. https://doi.org/10.1016/j.ygyno.2016.05.005

Vancouver

Schou Karlsen NM, Karlsen MA, Høgdall E, Nedergaard L, Christensen IJ, Høgdall C. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecologic Oncology. 2016 jul.;142(1):50-3. https://doi.org/10.1016/j.ygyno.2016.05.005

Author

Schou Karlsen, Nikoline Marie ; Karlsen, Mona Aarenstrup ; Høgdall, Estrid ; Nedergaard, Lotte ; Christensen, Ib Jarle ; Høgdall, Claus. / Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). I: Gynecologic Oncology. 2016 ; Bind 142, Nr. 1. s. 50-3.

Bibtex

@article{03445720e6b74077940315af1e0f4fce,

title = "Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT)",

abstract = "OBJECTIVE: The aim of the study was to evaluate the rate of relapse as well as disease-free, overall, and disease-specific survival in women with borderline ovarian tumour (BOT). Furthermore, the study aims to identify the clinical parameters correlated to relapse.METHODS: National clinical data of women diagnosed with BOT from January 2005 to January 2013 constituted the basis for our study population. The prognostic influence of clinical variables was evaluated using univariate and multivariate analyses.RESULTS: A total of 1143 women were eligible for analysis, with 87.9% in FIGO stage I and 12.1% in FIGO stages II-IV. Relapse of BOT was detected in 3.7%, hereof 40.5% with malignant transformation. The five-year disease-free survival was 97.6% in FIGO stage I and 87.3% in FIGO stages II-IV. Younger age, laparoscopic surgical approach, fertility sparing surgery, FIGO stages II-IV, bilateral tumour presence, serous histology, implants and microinvasion of the tumour were significantly associated with relapse in univariate analyses. The overall five-year survival rate was 92.2% in FIGO stage I and 89.0% in FIGO stages II-IV. Out of 77 deaths in total, only seven women died from BOT.CONCLUSIONS: A general favourable prognosis in women with BOT was confirmed in our study. Our findings indicate that systematic, long-term follow-up does not seem necessary in women treated for FIGO stage IA BOT with no residual disease or microinvasion.",

keywords = "Journal Article",

author = "{Schou Karlsen}, {Nikoline Marie} and Karlsen, {Mona Aarenstrup} and Estrid H{\o}gdall and Lotte Nedergaard and Christensen, {Ib Jarle} and Claus H{\o}gdall",

year = "2016",

month = jul,

doi = "10.1016/j.ygyno.2016.05.005",

language = "English",

volume = "142",

pages = "50--3",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "1",

}

RIS

TY - JOUR

T1 - Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT)

AU - Schou Karlsen, Nikoline Marie

AU - Karlsen, Mona Aarenstrup

AU - Høgdall, Estrid

AU - Nedergaard, Lotte

AU - Christensen, Ib Jarle

AU - Høgdall, Claus

PY - 2016/7

Y1 - 2016/7

N2 - OBJECTIVE: The aim of the study was to evaluate the rate of relapse as well as disease-free, overall, and disease-specific survival in women with borderline ovarian tumour (BOT). Furthermore, the study aims to identify the clinical parameters correlated to relapse.METHODS: National clinical data of women diagnosed with BOT from January 2005 to January 2013 constituted the basis for our study population. The prognostic influence of clinical variables was evaluated using univariate and multivariate analyses.RESULTS: A total of 1143 women were eligible for analysis, with 87.9% in FIGO stage I and 12.1% in FIGO stages II-IV. Relapse of BOT was detected in 3.7%, hereof 40.5% with malignant transformation. The five-year disease-free survival was 97.6% in FIGO stage I and 87.3% in FIGO stages II-IV. Younger age, laparoscopic surgical approach, fertility sparing surgery, FIGO stages II-IV, bilateral tumour presence, serous histology, implants and microinvasion of the tumour were significantly associated with relapse in univariate analyses. The overall five-year survival rate was 92.2% in FIGO stage I and 89.0% in FIGO stages II-IV. Out of 77 deaths in total, only seven women died from BOT.CONCLUSIONS: A general favourable prognosis in women with BOT was confirmed in our study. Our findings indicate that systematic, long-term follow-up does not seem necessary in women treated for FIGO stage IA BOT with no residual disease or microinvasion.

AB - OBJECTIVE: The aim of the study was to evaluate the rate of relapse as well as disease-free, overall, and disease-specific survival in women with borderline ovarian tumour (BOT). Furthermore, the study aims to identify the clinical parameters correlated to relapse.METHODS: National clinical data of women diagnosed with BOT from January 2005 to January 2013 constituted the basis for our study population. The prognostic influence of clinical variables was evaluated using univariate and multivariate analyses.RESULTS: A total of 1143 women were eligible for analysis, with 87.9% in FIGO stage I and 12.1% in FIGO stages II-IV. Relapse of BOT was detected in 3.7%, hereof 40.5% with malignant transformation. The five-year disease-free survival was 97.6% in FIGO stage I and 87.3% in FIGO stages II-IV. Younger age, laparoscopic surgical approach, fertility sparing surgery, FIGO stages II-IV, bilateral tumour presence, serous histology, implants and microinvasion of the tumour were significantly associated with relapse in univariate analyses. The overall five-year survival rate was 92.2% in FIGO stage I and 89.0% in FIGO stages II-IV. Out of 77 deaths in total, only seven women died from BOT.CONCLUSIONS: A general favourable prognosis in women with BOT was confirmed in our study. Our findings indicate that systematic, long-term follow-up does not seem necessary in women treated for FIGO stage IA BOT with no residual disease or microinvasion.

KW - Journal Article

U2 - 10.1016/j.ygyno.2016.05.005

DO - 10.1016/j.ygyno.2016.05.005

M3 - Journal article

C2 - 27168006

VL - 142

SP - 50

EP - 53

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -

ID: 176828163